BioPharmSignal logoBioPharmSignal

Biotech News

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics (LYRA)Lyra TherapeuticsEarnings

– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a

Related news

LYRALyra Therapeutics2025-08-12 20:01 EST

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

LYRALyra Therapeutics2025-05-06 20:01 EST

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

View all latest news

Lyra Therapeutics

Lyra Therapeutics is an otolaryngology company focused on chronic rhinosinusitis and upper-airway disease. Its platform uses localized delivery to treat difficult ENT conditions.

Recent company news

LYRALyra Therapeutics2026-04-17 12:00 EST

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

LYRALyra Therapeutics2026-01-12 12:00 EST

Lyra Therapeutics Provides Corporate Update

LYRALyra Therapeutics2025-11-12 21:01 EST

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

LYRALyra Therapeutics2025-10-06 11:00 EST

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

LYRALyra Therapeutics2025-08-12 20:01 EST

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
0.01 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States